CST, 87182S, LMO2 (E8K6I) Rabbit Monoclonal Antibody

Monoclonal Antibody for studying LMO2. Validated for WB,IF,F,ChIP,ChIP. Available in 2 sizes. Highly specific and rigorously validated in-house, LMO2 (E8K6I) Rabbit Monoclonal Antibody (CST #87182) is ready to ship. Product Usage Information For optimal ChIP and ChIP-seq results, use 5 μL of antibody and 10 μg of chromatin (approximately 4 x 10^6 cells) per IP. This antibody has been validated using SimpleChIP ® Enzymatic Chromatin IP Kits. Western Blotting: 1:1000 Immunofluorescence (Immunocytochemistry): 1:1600 - 1:6400 Flow Cytometry (Fixed/Permeabilized): 1:400 - 1:1600 Chromatin IP: 1:100 Chromatin IP-seq: 1:100 Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at -20°C. Do not aliquot the antibody. Protocol Available protocols: Western Blotting, Immunofluorescence (Immunocytochemistry), Flow Cytometry (Fixed/Permeabilized), Chromatin IP, Chromatin IP-seq Specificity / Sensitivity LMO2 (E8K6I) Rabbit Monoclonal Antibody recognizes endogenous levels of total LMO2 protein. This antibody also recognizes a non-specific band of unknown origin at 78 kDa. Testing of this antibody with positive and negative models by Flow Cytometry and Immunofluorescence corroborated specificity of this antibody. Species Reactivity: Human Source / Purification Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of human LMO2 protein. Background LIM domain only protein 2 (LMO2) is a transcriptional regulator that was first identified as a proto-oncogene activated by chromosomal translocations in T-cell acute lymphocytic leukemia (T-ALL) (1). Since then, LMO2 has been found to be a master regulator essential for erythroid development, as evidenced by homozygous LMO2 knockouts resulting in embryonic lethality in mice (2). LMO2 is an intrinsically unstructured protein that does not bind DNA directly, but rather acts as a scaffolding protein that recruits various transcription factors via its tandem cysteine-rich LIM domains to form a multi-protein DNA binding complex (3,4). The LMO2 complex plays a major role in hematopoiesis and was originally shown to consist of the transcription factors TAL1, E47, and GATA-1 in erythroid lineage cells, but variations of this complex may contain alternate transcription factors including LYL1, TAL2, GATA-2, and GATA-3 (5-9). The LMO2 complex also requires interaction with LIM-domain binding protein 1 (LDB1), which is necessary for LMO2 protein stability (10-11). In addition to hematopoietic tissue, LMO2 is also expressed in embryonic brain tissue, where it associates with BEX2 and the transcription factor NSCL-2 (12). Aberrant LMO2 expression is observed in several types of hematopoietic cancers, including large diffuse B-cell lymphoma (DLBCL), B-cell acute leukemia, (B-ALL), acute myeloid leukemia (AML), and T-ALL (13-16). LMO2-mediated T-ALL is primarily caused by the translocation t(11;14)(p13;q11) with the gene from chromosome 14q11, or the t(7;11)(q35;p13) translocation involving from 7q35 (1). In addition to hematopoietic cancers, overexpression of LMO2 in prostate stromal cells also facilitates prostate cancer progression by inducing expression of Interleukin-11 (IL-11), which stimulates STAT3 signaling in these cells (17). Alternate Names Cysteine-rich protein TTG-2; LIM domain only 2; LIM domain only 2 (rhombotin-like 1); LIM domain only protein 2; LMO-2; LMO2; RBTN2; RBTNL1; RHOM2; rhombotin 2; Rhombotin-2; rhombotin-like 1; T-cell translocation gene 2; T-cell translocation protein 2; TTG2 Specification REACTIVITY: H SENSITIVITY: Endogenous MW (kDa): 18 Source/Isotype: Rabbit IgG